Johnson & Johnson has been the subject of investment-related activities, with a significant number of financial institutions adjusting their stakes in the company. Major firms such as Jump Financial LLC and Harvest Portfolios Group Inc. decreased their holdings, while others like Guggenheim Capital LLC and WPG Advisers LLC acquired new shares. There is an evident trend of more firms reducing their holdings rather than acquiring. The company is channeling significant investments in U.S. manufacturing expansion, with plans to invest $2 billion, potentially boosting its R&D and U.S portfolio, in the face of looming drug tariffs. The firm has experienced difficulties with its combination arthritis drug, leading to discontinued development following a trial setback. J&J has received FDA Priority Review for its high-risk non-muscle invasive bladder cancer medication, and it has plans to launch NJBioFutures to prepare the future workforce.
Johnson Johnson JNJ News Analytics from Tue, 10 Dec 2024 13:10:08 GMT to Sat, 30 Aug 2025 23:32:05 GMT -
Rating 0
- Innovation 5
- Information 10
- Rumor -3
